Showing results (11-20 of 51) with videos related to
Sort By:
Pageof 6
Current Opinion in Clinical Nutrition and Metabolic Care|September 14, 2011
Thiamine supplementation in the critically illWilliam Manzanares, Gil HardyCurrent Opinion in Clinical Nutrition and Metabolic Care|October 12, 2011
Clinical and nutritional benefits of cysteine-enriched protein supplementsRobert A McPherson, Gil HardyNutrition (Burbank, Los Angeles County, Calif.)|June 5, 2002
Glutamine in pediatrics: where next?Patrick A Ball, Gil HardyCurrent Opinion in Clinical Nutrition and Metabolic Care|April 7, 2009
Nutrition therapy for acute renal failure: a new approach based on 'risk, injury, failure, loss, and end-stage kidney' classification (RIFLE)Erick Valencia, Angela Marin, Gil HardyNutrition (Burbank, Los Angeles County, Calif.)|March 13, 2023
Thiamine pharmaconutrition in sepsis: Monotherapy, combined therapy, or neither? Current evidence on safety and efficacyJuan Novoa, Gil Hardy, William ManzanaresNutrition (Burbank, Los Angeles County, Calif.)|May 3, 2002
Impact of oral L-glutamine on glutathione, glutamine, and glutamate blood levels in volunteersErick Valencia, Angela Marin, Gil HardyNutrition (Burbank, Los Angeles County, Calif.)|October 13, 2020
Pharmaconutrition revisited for critically ill patients with coronavirus disease 2019 (COVID-19): Does selenium have a place?William Manzanares, Eduardo Moreira, Gil HardyCurrent Opinion in Clinical Nutrition and Metabolic Care|October 24, 2002
Nutraceuticals: a pharmaceutical viewpoint: IGil Hardy, Ines Hardy, Bruce McElroyNutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition|February 7, 2012
Selenium supplementation in the critically illGil Hardy, Ines Hardy, William ManzanaresCurrent Opinion in Clinical Nutrition and Metabolic Care|October 15, 2003
Nutraceuticals--a pharmaceutical viewpoint: part IIGil Hardy, Ines Hardy, Patrick A BallPageof 6